Ezharima launched in Japan as first dual EZH1 and EZH2 inhibitor therapy for leukemiaLymphoma
EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years
EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years
Allam was serving recently as the CEO at Public Investment Fund
Positive opinions based on significant survival benefit
The product is backed by required scientific proof and comparative bioequivalence studies
Her previous role at Novartis, where she was general manager, data & digital, in global drug development, also included accountability for driving the DCT strategy, programs and platforms
UHI is envisioned as a foundational layer of the Ayushman Bharat Digital Mission and aims to enable interoperability in health services in India through open protocols
The company will submit an action plan on the observations and will engage with US FDA for next steps.
Sanjeev is currently the Country President for AstraZeneca Malaysia
Subscribe To Our Newsletter & Stay Updated